11 results on '"Clofazimina"'
Search Results
2. Lobomykose Erfolgreiche Therapie mit Clofazimin und Itrakonazol bei einem 46-jährigen Patienten nach 32-jähriger Krankheitsdauer
- Author
-
A. Chrusciak Talhari, Marcellus Fischer, Sinésio Talhari, and Dieter Reinel
- Subjects
Clofazimin ,Gynecology ,medicine.medical_specialty ,business.industry ,Triazole derivatives ,Medicine ,Dermatology ,business ,Clofazimina - Abstract
Die Lobomykose, verursacht durch Lacazia loboi, ist eine chronisch verlaufende tiefe Mykose und kommt ausschlieslich in Mittel- und Sudamerika vor. Klinisch ist die Erkrankung durch konfluierende, braunlich glanzende Knoten gekennzeichnet, die an Keloide erinnern. Die Lasionen befinden sich bevorzugt an den Extremitaten und im Gesicht. Als Erfolg versprechende Behandlungsmethode galt bisher nur die chirurgische Exzision. Wir berichten uber einen erfolgreichen Behandlungsversuch nach einer 1-jahrigen Kombinationstherapie mit Clofazimin (100 mg/Tag) und Itrakonazol (100 mg/Tag). Klinisch und histologisch konnte eine Vollremission beobachtet werden.
- Published
- 2002
3. Miscellaneous treatments: thalidomide, potassium iodide, levamisole, clofazimine, colchicine, and d-Penicillamine
- Author
-
Miguel Sanchez
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Anti-Inflammatory Agents ,chemistry.chemical_element ,Dermatology ,Pharmacology ,Clofazimina ,Iodine ,Clofazimine ,Skin Diseases ,chemistry.chemical_compound ,Adjuvants, Immunologic ,Internal medicine ,medicine ,Humans ,Colchicine ,Drug Approval ,Chemotherapy ,United States Food and Drug Administration ,business.industry ,Penicillamine ,Potassium Iodide ,Levamisole ,Drug Utilization ,United States ,Thalidomide ,Endocrinology ,chemistry ,Dermatologic Agents ,business ,medicine.drug - Published
- 2000
4. Varón, natural de Brasil, que consulta por lesiones cutáneas y fiebre
- Author
-
Irene Cortés, María Teresa de Guzmán, Juan Pedro Zabaleta, and Jose Antonio Aramburu
- Subjects
Microbiology (medical) ,medicine.medical_specialty ,Tratamiento farmacologico ,business.industry ,medicine ,Clofazimina ,business ,Dermatology - Published
- 2009
5. WBC count and functional changes induced by co-administration of clofazimine and clarithromycin, in single and multiple doses, in Wistar rats
- Author
-
Ana Maria de Souza, Regina Helena Costa Queiroz, Flávia Aparecida Paina, Cristiane Fernandes de Freitas Tavares, and Julise Cunha Miranda
- Subjects
medicine.medical_specialty ,Clofazimina ,Phagocytosis ,Clofazimina^i2^sestudo experimen ,Leucócitos ,lcsh:RS1-441 ,Pharmacology ,Peripheral blood mononuclear cell ,Clofazimine ,Clofazimine^i1^sexperimental st ,Blood cell ,lcsh:Pharmacy and materia medica ,Clarithromycin ,Leprosy ,medicine ,Claritromicina^i2^sestudo experimen ,Leukocytes ,Hanseníase^i2^stratame ,Leprosy^i1^streatm ,General Pharmacology, Toxicology and Pharmaceutics ,Adverse effect ,Claritromicina ,Hanseníase ,business.industry ,Fagocitose ,Mycobacterium avium^i1^streatm ,Clofazimine^i1^sadverse effe ,Mycobacterium avium^i2^sinfecç ,Mycobacterium avium^i1^sinfecti ,Oxidative burst ,Surgery ,Respiratory burst ,Burst oxidativo ,medicine.anatomical_structure ,Claritromicina^i2^sefeitos adver ,Toxicity ,Clofazimina^i2^sefeitos adver ,Clarithromycin^i1^sadverse effe ,Clarithromycin^i1^sexperimental st ,business ,Mycobacterium avium^i2^stratame ,medicine.drug ,Mycobacterium avium - Abstract
Clofazimine and clarithromycin are used to treat leprosy and infections caused by Mycobacterium avium complex. Little data on the toxicity of co-administration of these two drugs are available. Here we evaluated the potential adverse effects of polytherapy with these two drugs in male Wistar rats by determining WBCs counts and other blood cell counts, neutrophilic phagocytosis, and burst oxidative, by flow cytometry. We observed an increase in WBCs, in multiple-dose regimens, and in polymorphonuclear cells, in both single- clarithromycin only and multiple dose regimens. We also observed a reduction in mononuclear cell counts in single and multiple doses. The drugs seem to reverse the mononuclear and polymorphonuclear cell ratio. An increase in oxidative burst was observed in animals treated with the drugs administered either individually or combined. In conclusion, clofazimine and clarithromycin change WBCs counts. Our results may contribute for a better understanding of the mechanisms related to the effects of co-administrating the two drugs.Clofazimina e laritromicina são utilizadas no tratamento da hanseníase e em infecções causadas pelo complexo Mycobacterium avium. Devido à escassez de dados sobre a toxicidade de esquemas terapêuticos que associam estes fármacos, este estudo teve por objetivo avaliar os efeitos adversos desta terapia, em ratos machos Wistar, por meio da determinação da contagem global e específica de leucócitos e ensaios de fagocitose e burst oxidativo de neutrófilos por citometria de fluxo. Houve aumento do número de leucócitos (dose múltipla) e de células polimorfonucleares (doses única e múltipla) nos grupos tratados com claritromicina em monoterapia ou associada à clofazimina e redução das células mononucleares, em doses única e múltipla, nos mesmos grupos. Os fármacos parecem inverter a proporção entre células mono e polimorfonucleares. Observou-se aumento do burst oxidativo nos animais tratados com os fármacos isolados ou associados. Concluindo, clofazimina e claritromicina provocam alterações leucocitárias e os resultados podem contribuir para melhor entendimento dos mecanismos relacionados aos efeitos da administração dos fármacos em associação.
- Published
- 2012
6. Lesiones cutáneas múltiples en un paciente colombiano
- Author
-
Virginia Velasco-Tirado, Angel Santos-Briz, Moncef Belhassen-García, and Gonzalo Nieto-González
- Subjects
Microbiology (medical) ,medicine.medical_specialty ,Tratamiento farmacologico ,business.industry ,MEDLINE ,medicine ,Clofazimina ,business ,Dermatology - Published
- 2014
7. Hematological, hemostatic and biochemical alterations induced by clofazimine and clarithromycin, in single and multiple doses, in rats
- Author
-
Regina Helena Costa Queiroz, Flávia Aparecida Paina, and Ana Maria de Souza
- Subjects
Microbiology (medical) ,Prothrombin time ,Clofazimina ,Tuberculosis ,medicine.diagnostic_test ,business.industry ,Hematological changes ,Pharmacology ,medicine.disease ,Clofazimine ,Infectious Diseases ,Alterações hematológicas ,Clarithromycin ,Toxicity ,Medicine ,Parasitology ,Leprosy ,business ,Adverse effect ,Claritromicina ,medicine.drug ,Partial thromboplastin time ,Mycobacterium avium - Abstract
Claritromicina e clofazimina têm sido utilizadas no tratamento da hanseníase, tuberculose e infecções causadas pelo complexo Mycobacterium avium. Como os dados sobre a toxicidade de esquemas terapêuticos que incluem estes fármacos são escassos, este estudo teve como objetivo determinar os efeitos adversos destas terapias, por meio da avaliação dos parâmetros hematológicos, hemostáticos e bioquímicos. Os fármacos foram administrados em ratos machos Wistar, em monoterapia, em regime de doses única e múltipla. Claritromicina provocou aumento de leucócitos mono e polimorfonucleares. Ambos os fármacos inverteram a proporção entre células mono e polimorfonucleares e provocaram aumento do número de células polimorfonucleares e células em degeneração. Clofazimina e claritromicina prolongaram o tempo de protrombina e claritromicina também prolongou o tempo de tromboplastina parcial ativa. Claritromicina causou aumento de bilirrubinas total e direta e, ambos os fármacos, elevaram os níveis plasmáticos de gama-glutamiltransferase. Portanto, clofazimina e claritromicina induzem alterações hematológicas, hemostáticas e hepáticas. Clarithromycin and clofazimine have been used to treat leprosy, tuberculosis and infections caused by the Mycobacterium avium complex. Since there is a scarcity of data on the toxicity of therapeutic regimens that include these drugs, this study had the aim of determining the adverse effects of these therapies, through evaluation of hematological, hemostatic and biochemical parameters. The drugs were administered to male Wistar rats, as monotherapy, in regimens of single and multiple doses. Clarithromycin caused increases in the numbers of mononuclear and polymorphonuclear leukocytes. Both of the drugs inverted the proportions between mononuclear and polymorphonuclear cells and increased the numbers of polymorphonuclear cells and degenerating cells. Clofazimine and clarithromycin prolonged the prothrombin time and clarithromycin also prolonged the activated partial thromboplastin time. Clarithromycin caused increases in total and direct bilirubin. Both of the drugs increased the plasma levels of gamma-glutamyltransferase. Therefore, clofazimine and clarithromycin induce hematological, hemostatic and hepatic changes.
- Published
- 2008
8. Cheilitis granulomatosa Miescher: treatment with clofazimine and review of the literature
- Author
-
Erwin Löhle, Gerd Jürgen Ridder, and Milo Fradis
- Subjects
medicine.medical_specialty ,Adolescent ,Lip swelling ,Clofazimina ,030226 pharmacology & pharmacy ,Clofazimine ,03 medical and health sciences ,0302 clinical medicine ,Melkersson–Rosenthal syndrome ,medicine ,Humans ,030223 otorhinolaryngology ,Coloring Agents ,Melkersson-Rosenthal Syndrome ,business.industry ,Anti-Inflammatory Agents, Non-Steroidal ,General Medicine ,medicine.disease ,Dermatology ,Alternative treatment ,Surgery ,Otorhinolaryngology ,Female ,Differential diagnosis ,business ,Miescher's cheilitis ,medicine.drug - Abstract
Cheilitis granulomatosa Miescher is a rare condition of unknown cause characterized by intermittent lip swelling that gradually persists and causes cosmetic deformity. We report the case of a young woman with cheilitis granulomatosa as a monosymptomatic manifestation of Melkersson-Rosenthal syndrome successfully treated by the antileprosy agent clofazimine, and propose clofazimine as an alternative treatment in cases refractory to corticosteroids. The differential diagnosis and current methods of treatment are summarized, and the literature is reviewed and discussed.
- Published
- 2001
9. Aktueller Stand der Therapie mit Clofazimin (Lampren®) bei Lepra, Erythema leprosum und anderen Dermatosen nach Abgabe des Medikamentes von Novartis an die WHO
- Author
-
C H Sunderkötter and H Lan Ma
- Subjects
medicine.medical_specialty ,Erythema ,business.industry ,Treatment outcome ,Dermatology ,Clofazimina ,medicine.disease ,Clofazimine ,Erythema nodosum leprosum ,Donation ,medicine ,Leprosy ,medicine.symptom ,business ,medicine.drug ,Antibacterial agent - Published
- 2005
10. Ashy Dermatosis - Treatment with Clofazimine
- Author
-
Mónica Caetano, Manuela Selores, Rosário Alves, and Teresa Pinto-Almeida
- Subjects
Clofazimina ,Pathology ,medicine.medical_specialty ,Erythema ,business.industry ,Doenças da pele ,lcsh:RL1-803 ,medicine.disease ,Dermatology ,Complete resolution ,Asymptomatic ,lcsh:Infectious and parasitic diseases ,Clofazimine ,Alterações da pigmentação ,lcsh:Dermatology ,Etiology ,Medicine ,lcsh:RC109-216 ,Histopathology ,Erythema dyschromicum perstans ,medicine.symptom ,business ,Eritema ,Pigmentation disorder ,medicine.drug - Abstract
Ashy dermatosis, or erythema dyschromicum perstans, is a rare dermatosis of unknown etiology. The au- thors report the case of a 46-year-old healthy man that presented with a 1-year history of asymptomatic gray macules on the trunk. The constellation of clinical features, laboratory studies and histopathology allowed the diagnosis of Ashy dermatosis. Treatment with oral clofazimine was started, with complete resolution of the cutaneous lesions and without relapses after 6 months of follow-up. Therapeutic options for Ashy dermatosis are numerous, but none with consistent efficacy. Treatment with clofazimine has been attempted not only for its cosmetic effect, producing a uniform colouring of the skin that masks the pigmented areas, but also because its beneficial effect may be mediated by anti-inflammatory and immunomodulatory actions. This report supports the therapeutic efficacy of clofazimine in a patient with Ashy der- matosis.KEYWORDS – Clofazimine; Erythema; Pigmentation disorders; Skin diseases.
- Published
- 2013
11. Eritema nudoso leproso persistente y enteropatía letal por clofazimina
- Author
-
Yenny Gómez, Rafael Pinto, Gerzaín Rodríguez, and Fernando López
- Subjects
lcsh:Arctic medicine. Tropical medicine ,Antimycobacterial Agents ,lcsh:RC955-962 ,lcsh:Medicine ,Acute ,Clofazimina ,Clofazimine ,General Biochemistry, Genetics and Molecular Biology ,Disease course ,anti-bacterial agents/adverse effects ,Abdomen ,erythema nodosum ,clofazimine ,Medicine ,Gastrointestinal agent ,Medical treatment ,business.industry ,lcsh:R ,lepromatous leprosy/complications ,acute ,Anti-bacterial agents/adverse effects ,drug therapy ,Lepromatous leprosy/complications ,Erythema nodosum leprosum ,Drug therapy ,Erythema nodosum ,business ,Humanities ,abdomen - Abstract
7 Páginas Introducción. La enteropatía por clofazimina es una complicación grave de este fármaco, cuando se usa a dosis altas para la reacción leprosa tipo 2 y otras enfermedades. Objetivo. Presentar una mujer de 31 años con síntomas de lepra, incluidos episodios de eritema nudoso leproso, agravados durante el embarazo, sin diagnóstico médico preciso. Relatar la evolución de su enteropatía letal por clofazimina. Materiales y métodos. Entrevista con la paciente y sus familiares, revisión de la historia clínica y de la literatura pertinente. Resultados. La paciente presentó lesiones cutáneas anestésicas y varios episodios de eritema nudoso, agravados durante sus embarazos. Luego de epistaxis repetidas y perforación del tabique nasal, se diagnóstico lepra lepromatosa, 12 años después de numerosas consultas médicas. Su esposo y su hija de 12 años presentaron signos de lepra para la cual se trataron. La paciente tuvo episodios de reacción tipo 2 durante la poliquimioterapia, para los cuales recibió 400 mg diarios de clofazimina. A los dos meses de este tratamiento comenzó a presentar dolor abdominal persistente durante más de un año, muy serio y episódicamente exacerbado, manejado con analgésicos y antiespasmódicos, incluida la morfina. Tuvo, además, diarrea, estreñimiento, náuseas, pérdida de peso y adenopatías mesentéricas. Falleció sin diagnóstico de su afección intestinal. No se hizo autopsia. Conclusiones. La clínica final de la paciente sugiere que se trata de un caso de enteropatía letal por clofazimina, una complicación que no se había reconocido previamente en nuestros pacientes. Es necesario aumentar el conocimiento de la lepra entre los médicos.
- Published
- 2009
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.